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Abstract 
Rationale: Prostate cancer (PCa) recurrences after surgery frequently occur. To improve the 
outcome after surgical resection of the tumor, the theranostic multimodal anti-PSMA targeting 
agent 111In-DTPA-D2B-IRDye700DX was developed and characterized for both pre- and 
intra-operative tumor localization and eradication of (residual) tumor tissue by PSMA-targeted 
photodynamic therapy (tPDT), which is a highly selective cancer treatment based on targeting 
molecules conjugated to photosensitizers that can induce cell destruction upon exposure to 
near-infrared (NIR) light. 
Methods: The anti-PSMA monoclonal antibody D2B was conjugated with IRDye700DX and DTPA 
and subsequently radiolabeled with 111In. To determine the optimal dose and time point for tPDT, 
BALB/c nude mice with PSMA-expressing (PSMA+) s.c. LS174T-PSMA xenografts received the 
conjugate (24-240 µg/mouse) intravenously (8 MBq/mouse) followed by µSPECT/CT, near-infrared 
fluorescence imaging, and ex vivo biodistribution at 24, 48, 72 and 168 h p.i. Tumor growth of 
LS174T-PSMA xenografts and overall survival of mice treated with 1-3 times of NIR light irradiation 
(50, 100, 150 J/cm2) 24 h after injection of 80 µg of DTPA-D2B-IRDye700DX was compared to 
control conditions. 
Results: Highest specific tumor uptake was observed at conjugate doses of 80 µg/mouse. 
Biodistribution revealed no significant difference in tumor uptake in mice at 24, 48, 72 and 168 h p.i. 
PSMA+ tumors were clearly visualized with both µSPECT/CT and NIR fluorescence imaging. Overall 
survival in mice treated with 80 µg of DTPA-D2B-IRDye700DX and 1x 150 J/cm2 of NIR light at 24 
h p.i. was significantly improved compared to the control group receiving neither conjugate nor NIR 
light (73 days vs. 16 days, respectively, p=0.0453). Treatment with 3x 150 J/cm2 resulted in 
significantly prolonged survival compared to treatment with 3x 100 J/cm2 (p = 0.0067) and 3x 50 
J/cm2 (p = 0.0338).  
Principal conclusions: 111In-DTPA-D2B-IRDye700DX can be used for pre- and intra-operative 
detection of PSMA+ tumors with radionuclide and NIR fluorescence imaging and PSMA-targeted 
PDT. PSMA-tPDT using this multimodal agent resulted in significant prolongation of survival and 
shows great potential for treatment of (metastasized) prostate cancer. 
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Introduction 
Despite improvements in diagnosis and therapy, 
prostate cancer (PCa) remains a significant health 
problem with 180,890 estimated new cases and 26,120 
estimated deaths in the US in 2016 [1]. At present, the 
curative treatment option for localized stages of PCa 
is radical prostatectomy, which may include extended 
lymph node dissection in case of intermediate- and 
high-risk localized PCa [2, 3]. Unfortunately, two 
main factors limit the success of surgical procedures: 
First, translation of pre-operatively obtained images 
to the surgical field can be challenging, increasing the 
risk for smaller tumor lesions to be missed by the 
surgeon. Secondly, wide local excision of tumor 
lesions in the lower pelvis may be precluded due to 
close proximity of the lesions to important healthy 
structures such as urinary bladder wall or erectile 
nerves, leading to positive surgical margins after 
radical prostatectomy in 11-48% of patients [4-6]. In 
both cases, lesions may grow out to cause recurrence 
of the disease.  
Photodynamic therapy is an ablative procedure, 
in which tumor cells can be destroyed efficiently by 
irradiation of light of a specific wavelength, which 
activates a previously administered photosensitizer 
(PS). Upon absorption of photons, the PS is activated 
and undergoes photochemical reactions producing 
reactive oxygen species (ROS) by transfer of energy 
from the PS to the oxygen present in the tissue. 
Consequently, the produced ROS such as hydroxyl 
radicals, hydrogen peroxide, and superoxide can 
cause cellular damage. Clinical studies revealed that 
photodynamic therapy can be curative, particularly in 
early stage tumors [7]. In addition, the survival in 
patients with inoperable cancers can be prolonged. 
Even though the principle of photodynamic therapy 
has been known for several decades, it has not been 
fully exploited for clinical uses, yet. The major reasons 
that restrict full clinical exploitation of conventional 
PDT are insufficient delivery of the photosensitizer to 
tumor tissue, resulting in a limited anti-tumor effect. 
Moreover, especially in the non-targeted approach, 
accumulation of the photosensitizer into healthy 
tissues could result in adverse effects such as 
phototoxic and photoallergic reactions.  
To overcome these obstacles, a targeted 
approach of photodynamic therapy has been 
developed. In this so-called targeted photodynamic 
therapy (tPDT), selectivity is enhanced by conjugation 
of the photosensitizer to a tumor targeting vehicle 
thereby allowing selective and effective treatment of 
tumor remnants [8]. The prostate-specific membrane 
antigen (PSMA) is an integral membrane glycoprotein 
which is overexpressed in the majority of PCa [9]. Due 
to its selective overexpression in 90-100% of local PCa 
lesions, malignant lymph nodes, and bone metastases 
[10-12], PSMA has been recognized as an ideal target 
for imaging and therapy of PCa [13-17].  
To address the issue of intra-operative tumor 
localization and eradication of residual tumor tissue 
to improve treatment of PCa, we developed a 
theranostic approach using the anti-PSMA mAb D2B 
labeled with 111In and conjugated to the 
photosensitizer IRDye700DX. This multimodal 
PSMA-targeting agent can be used for theranostic 
applications: First, the extent of the tumor can be 
estimated pre-operatively by SPECT/CT. Second, the 
radiosignal may be used for surgical guidance using a 
gamma probe during surgery. Third, the fluorescence 
signal of the photosensitizer IRDye700DX may be 
used for intra-operative visualization of tumor tissue 
with near-infrared fluorescence (NIRF) imaging, to 
guide resection of the tumor and to mark potential 
areas with tumor remnants for tPDT. Finally, our 
theranostic agent allows intra-operative tPDT for 
tumor-specific destruction of residual tumor tissue 
that could not be removed surgically, for instance in 
the lower pelvis where proximity of the prostate to 
rectum, sphincter and erectile nerves precludes wide 
local excision.  
Materials and Methods 
Reagents 
The mAb D2B (IgG1) was derived from mice that 
were immunized three times with a cell lysate of 
membranes of LNCaP cells [18-20]. Mice were also 
boosted with a recombinant form of PSMA produced 
in bacteria. D2B IgG was purified from hybridoma 
culture supernatant by Protein A affinity 
chromatography [18, 20]. IRDye700DX NHS ester was 
purchased from LI-COR Biosciences (Lincoln, NE).  
Synthesis of IRDye700DX-D2B-DTPA 
170 µl of 1 M NaHCO3, pH 8.5 was added to D2B 
IgG (5 mg in 1700 µl PBS, 32 nmol) for conjugation of 
D2B with N-hydroxysuccinimide (NHS)-IRDye700DX 
(LI-COR Biosciences) in DMSO, with a 10-fold molar 
excess of NHS-IRDye700DX (650 μg, 333 nmol). After 
1 h of incubation at room temperature on an orbital 
shaker in the dark, 650 µg (1000 nmol) of 
p-isothiocyanatobenzyl-diethylene-triamine-penta-ac
etic acid (ITC-DTPA) (Macrocyclics, Dallas, TX) in 
DMSO was added to the reaction mix in 190 µl of 1 M 
NaHCO3, pH 9.5, in a 31-fold molar excess, which 
under such circumstances commonly leads to a 
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substitution rate around 3 [21]. DTPA was conjugated 
to the lysine residues of the antibody. After 1 h of 
incubation at room temperature on an orbital shaker 
in the dark, the reaction mixture was dialyzed for 3 
days in a Slide-A-Lyzer (10-kDa cutoff, Thermo 
Scientific, Schwerte, Germany) against 0.25 M NH4Ac, 
pH 5.4. The dialysis buffer was replaced 2x per day 
during the 3-day dialysis period. The 
photosensitizer-to-antibody substitution ratio of the 
purified conjugate was determined with an Ultrospec 
2000 spectrophotometer (Pharmacia Biotech, 
Freiburg, Germany) at wavelengths of 280 nm and 689 
nm and was calculated using the formula: 
substitution ratio = 0.875*E689/(E280-(0.03*E689)). The 
0.875 represents the ratio between the extinction 
coefficient at 280 and 689 nm, and 0.03 is an 
estimation for IRDye700DX signal contributing to the 
absorption, as indicated by the manufacturer. The 
molar substitution ratio of the conjugate (700DX-D2B) 
used in these studies was 3.3. 
Radiolabeling of IRDye700DX-D2B-DTPA 
For in vitro studies, 25 µg of 
IRDye700DX-D2B-DTPA was radiolabeled with 25 
MBq 111In (Mallinckrodt, Petten, the Netherlands) in 
0.5 M MES buffer pH 5.4 (three times the volume of 
111In-chloride) and incubated during 30 min at room 
temperature under metal-free conditions. Following 
incubation, 50 mM EDTA was added to the final 
concentration of 5 mM to chelate unincorporated 111In. 
The labeling efficiency was determined by instant thin 
layer chromatography (ITLC) using 0.1 M citrate 
buffer, pH 6.0, as the mobile phase. Labeling 
efficiency was 86%, and after PD10 purification 
radiochemical purity exceeded 95%. 
For the protein dose escalation and time 
optimization study (24, 80, and 240 µg/mouse), 150, 
450, and 1200 µg of IRDye700DX-D2B-DTPA was 
radiolabeled with 50 MBq 111In. The labeling efficiency 
was 81, 93, and 96 % for the 24, 80, and 240 µg group, 
respectively. 111In-DTPA-D2B-IRDye700DX was 
purified by gel filtration on a PD-10 column, and the 
radiochemical purity of the final dual-labeled tracer 
was ≥ 97%, as determined by ITLC. 
Serum stability 
Samples of commercial mouse serum purchased 
from Bodinco B.V. (Alkmaar, the Netherlands) were 
used to determine the in vitro serum stability of 
111In-DTPA-D2B-IRDye700DX (10 µg D2B, 0.37 
MBq/µg) by ITLC using 0.1 M citrate buffer, pH 6.0, 
as the mobile phase. Stability was evaluated at 0, 0.5, 
2.5, 6, and 24 h incubation at 37 ⁰C. In addition, 
fluorescence intensity at each of these time points was 
measured on a TECAN infinite M200 Pro in serum 
and PBS in triplicate. Fluorescence intensity at t=0 was 
set to 100% and all other time points were analyzed in 
correlation to t=0. 
Cell culture 
The PSMA-transfected colon carcinoma cell line 
LS174T-PSMA was cultured in RPMI 1640 medium, 
supplemented with 10% fetal calf serum (Life 
technologies, Carlsbad, CA) and 2 mM of glutamine 
in the presence of 0.3 mg/mL G418 geneticin [20]. 
PSMA-negative LS174T-wildtype colon carcinoma 
cells were cultured in RPMI 1640 medium, 
supplemented with 10% fetal calf serum and 2 mM of 
glutamine. 
Immunoreactivity 
The immunoreactive fraction of the dual-labeled 
111In-DTPA-D2B-IRDye700DX was compared to that 
of 111In-DTPA-D2B using freshly trypsinized 
LS174T-PSMA cells in triplicate, essentially as 
described by Lindmo et al [22]. Briefly, a serial 
dilution of LS174T-PSMA cells (6.6 x 105 to 2.1 x 107 
cells/mL) in 0.5 mL RPMI medium containing 0.5% 
BSA was incubated at 37 °C for 1 h with 0.1 pmol 
111In-DTPA-D2B-IRDye700DX (250 Bq). An excess of 
unlabeled DTPA-D2B-IRDye700DX (1,300 pmol) was 
added to a duplicate of the lowest cell concentration 
to determine nonspecific binding [20]. After 
incubation, cells were spun down and the pellet was 
washed with binding buffer (500 μL RPMI medium 
containing 0.5% BSA). The activity in the vials and in 
the cell pellet was determined in the gamma counter 
(2480 WIZARD2 Automatic Gamma Counter, 
PerkinElmer). The inverse of the speciﬁc cell bound 
activity was plotted against the inverse of the cell 
concentration, and the immunoreactive fraction was 
calculated from the y-axis intercept using GraphPad 
Prism software (version 5.03 for Windows; GraphPad 
Software, La Jolla, USA) [20]. 
Internalization capacity 
LS174T-PSMA cells were cultured in six-well 
plates to confluency and were incubated with 1.9 kBq 
of 111In-DTPA-D2B (3.2-3.5 ng/well) or 
111In-DTPA-D2B-IRDye700DX (2.6-2.7 ng/well) for 2, 
4, 24, and 48 h in 2 mL binding buffer (RPMI + 0.5% 
BSA) at 37 °C in a humidified atmosphere with 5% 
CO2. Nonspecific binding was determined by 
coincubation with unlabeled D2B (5 µg/well). After 
incubation, acid wash buffer (0.1 M HAc, 0.15 M 
NaCl, pH2.6) was added for 10 min to remove the 
membrane-bound fraction of the cell-associated 
111In-labeled compounds. Subsequently, cells were 
harvested from the six-well plates and the amount of 
membrane-bound and internalized activity was 
measured in a gamma counter. 
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Competitive binding assay 
The 50% inhibitory concentration (IC50) of D2B 
IgG and DTPA-D2B-IRDye700DX was determined as 
described previously using PSMA-expressing 
LS174T-PSMA cells in a competitive binding assay 
with 111In-labeled D2B as a tracer [19, 20, 23]. The 
LS174T-PSMA cells were grown in 6-well plates to 
confluency, followed by incubation on ice for 2 h in 1 
mL of binding buffer with 1.9 kBq of 111In-labeled D2B 
IgG (2.6 ng) and a series of increasing concentrations 
(0.005-300 nM) of unlabeled D2B IgG [19, 20]. After 
incubation, cells were washed with binding buffer 
and the cell-associated activity was measured in a 
gamma-counter [19, 20]. The IC50 values were 
calculated using GraphPad Prism software.  
PSMA-targeted photodynamic therapy in vitro  
PSMA+ LS174T-PSMA and PSMA- LS174T cells 
were seeded into transparent 48-well plates (Thermo 
Scientific) (150,000 cells/well) and incubated for 48 h 
in RPMI 1640 medium, supplemented with 10% fetal 
calf serum and 2 mM of glutamine in the presence of 
0.3 mg/mL G418 geneticin. On the day of the 
experiment, cells were washed once with PBS and 
medium was replaced by 10 µg/mL of the 
DTPA-D2B-IRDye700DX conjugate in RPMI (250 µl 
volume per well). As negative control for NIR light 
irradiation effects, cells were included that only 
received PBS without DTPA-D2B-IRDye700DX. After 
incubation for 1 h at 37 °C, cells were washed with 
PBS and 500 µl of RPMI medium was added to the 
cells. Subsequently, cells were irradiated with a NIR 
light–emitting diode that emits light at a wavelength 
of 670 to 710 nm [24]. The typical forward voltage was 
2.6 V creating a power output of 490 mW using 126 
individual LED bulbs to ensure homogenous 
illumination of the area of interest predefined as 5 x 3 
cm. The cells were irradiated at NIR radiant exposures 
of 2, 5, 10, 30, 50, 100, and 150 J/cm2. All in vitro 
experiments were carried out in triplicate. As control 
for cellular toxicity of the DTPA-D2B-IRDye700DX 
conjugate, cells incubated with DTPA-D2B- 
IRDye700DX that were not irradiated with NIR light 
were included. 
Analysis of phototoxicity in vitro 
Cytotoxic effects of photodynamic therapy with 
D2B-IRDye700DX were determined with a 
CellTiter-GloTM assay (Promega Benelux, Leiden, the 
Netherlands) according to the instructions of the 
manufacturer at 1 h after irradiation. Briefly, all cells 
were incubated for 1 h under light-protected 
conditions at room temperature. Subsequently, 
medium was replaced by 100 µl of RPMI and 100 µl of 
the CellTiter-GloTM reagent was added [25]. The 
48-well plates were shaken for 2 min and incubated 
for 10 min at room temperature. Of each well, 100 µl 
was transferred to a black flat-bottom 96-well plate. 
The intensity of the luminescent signal associated to 
the amount of ATP present in the cell lysates was 
measured on a TECAN infinite M200 Pro. Cell 
viability of control cells was set to 100% and cell 
viability of treated cells (NIR light + conjugate) was 
calculated in relation to this value. 
Animal tumor model 
Male BALB/c nude mice (Janvier, Le Genest 
Saint Isle, France), 8-10 weeks old, were housed in 
individually ventilated cages (5 mice per cage) under 
nonsterile standard conditions with free access to 
chlorophyll-free animal chow (Ssniff, Soest, the 
Netherlands) and water. Mice were subcutaneously 
inoculated with 2.5 x 106 PSMA+ LS174T-PSMA cells 
or PSMA- LS174T-wildtype cells in 200 μL of complete 
RPMI 1640 medium in the right flank. Xenografts 
grew to approximately 0.1 g in 7 days after tumor cell 
inoculation [20]. All experiments have been approved 
by the Central Committee on Animal 
Experimentation and institutional Animal Welfare 
Committee of the Radboud University Medical Center 
and were conducted in accordance to the guidelines of 
the Revised Dutch Act on Animal Experimentation. 
Humane endpoints were: tumor size, ulceration or 
invasive tumor growth, abnormal mobility due to 
tumor growth, other signs of severe clinical 
discomfort (dehydration, 15% weight loss in less than 
2 days). 
Dual-modality µSPECT/CT and NIRF imaging 
and biodistribution 
Male BALB/c nude mice (5 mice per group) with 
s.c. PSMA-expressing LS174T-PSMA tumors received 
30 µg of 111In-DTPA-D2B-IRDye700DX (5-8 
MBq/mouse), intravenously. All mice were imaged 
on both an IVIS fluorescence imaging system 
(Xenogen VivoVision IVIS Lumina II, Caliper Life 
Sciences, Lincolnshire, UK) with an acquisition time 
of 10 s, and a small-animal µSPECT/CT scanner 
(U-SPECT II, MILabs, Utrecht, the Netherlands) with 
a 1.0 diameter pinhole collimator tube (acquisition 
time: 15 min, 20 min, 26 min and 65 min at 24, 48, 72, 
and 168 h p.i., respectively) under inhalation 
anesthesia with isoflurane, followed by a CT scan 
(spatial resolution 160 μm, 65 kV, 615 μA) for 
anatomical reference. Scans were reconstructed with 
MILabs reconstruction software, using an 
ordered‐subset expectation maximization algorithm, 
energy window 154 ‐ 188 keV, 3 iterations, 16 subsets, 
and voxel size of 0.2 mm. SPECT/CT scans were 
analyzed and maximum intensity projections (MIPs) 
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were created using the Inveon Research Workplace 
software (IRW, version 4.1). NIRF images were 
analyzed using Living Image software version 4.2. To 
determine the time point at which the highest tumor 
accumulation of 111In-DTPA-D2B-IRDye700DX was 
reached, at 24, 48, 72, and 168 h p.i. 5 mice were 
euthanized with CO2/O2 asphyxiation after scanning. 
Tissues of interest (tumor, muscle, lung, spleen, liver, 
kidneys, stomach, pancreas, duodenum, and prostate) 
were dissected, weighed and measured for 
radioactivity in a gamma counter (2480 WIZARD2 
Automatic Gamma Counter, PerkinElmer), as 
described previously [19, 20, 26]. Blood samples were 
obtained by heart puncture. An aliquot of the injected 
dose was counted simultaneously on the gamma 
counter to allow calculation of the uptake of 
radioactivity in each tissue as a fraction of the injected 
dose. 
In a biodistribution study, male BALB/c nude 
mice (5 mice per group) with s.c. PSMA-expressing 
LS174T-PSMA tumors received 24, 80, or 240 µg of 
111In-DTPA-D2B-IRDye700DX (8 MBq/mouse), 
intravenously. At 24 h after injection, all mice were 
imaged on both an IVIS fluorescence imaging system 
and a µSPECT/CT scanner as described above, 
followed by euthanasia with CO2/O2 asphyxiation. 
Tissues of interest (tumor, muscle, lung, spleen, liver, 
kidneys, stomach, pancreas, duodenum, and prostate) 
were dissected, weighed and measured for 
radioactivity in a gamma counter as described above. 
PSMA-targeted photodynamic therapy in vivo  
Mice with s.c. PSMA+ LS174T-PSMA tumors 
were block randomized into 6 groups of 7 animals 
based on tumor size at 7 days after inoculation of the 
tumor cells. Mice received 80 µg of 
DTPA-D2B-IRDye700DX intravenously via the tail 
vein followed by exposure to different NIR light 
irradiation regimens at 24h after injection of the 
conjugate. For NIR light irradiation, mice were placed 
under the NIR light–emitting diode that emits light at 
a wavelength of 670 to 710 nm [24]. The typical 
forward voltage was 2.6 V creating a power output of 
490 mW using 126 individual LED bulbs to ensure 
homogenous illumination of the area of interest 
predefined as 5 x 3 cm. The distance from diode to 
skin surface was 5 cm. Seven mice did not receive the 
tracer and were not irradiated (control group).  
Previously, unconjugated D2B was shown to 
have no therapeutic efficacy [27]. To determine the 
therapeutic effect of D2B-IRDye700DX itself 
DTPA-D2B-IRDye700DX was tested in mice that did 
not receive irradiation after administration of the 
conjugate. This condition was compared to mice that 
did not receive the conjugate but did receive NIR light 
irradiation and to mice that received neither conjugate 
nor NIR light irradiation. In addition, mice with s.c. 
PSMA-negative LS174T-wildtype tumors were 
included as negative control. These mice received 80 
µg of DTPA-D2B-IRDye700DX intravenously 
followed by exposure to different NIR light 
irradiation regimens at 24h after injection of the 
conjugate. 
To determine the treatment efficacy, the 
diameter of the tumors was measured twice a week in 
three dimensions with an external caliper by the same 
person for all measurements. This person was blinded 
for group stratification. Tumor volumes were 
calculated using the following formula: (length x 
width x depth)/2. Mice were observed daily, and 
were euthanized by CO2/O2 asphyxiation when 
tumor volume reached more than 1000 mm3. In 
addition, mice were removed from the experiment 
humane endpoints were reached, scored by a blinded 
biotechnician. Overall survival was defined as the day 
when tumors reached a size of 1000 mm3 or at which 
humane endpoints were reached. Progression-free 
survival was defined as the time point after NIR light 
exposure at which tumors showed progression in size 
after a period of regression/stable disease. Blood 
samples of 0.1 mL were collected via submandibular 
bleeding before and after therapy to determine blood 
creatinine and liver enzymes (ASAT, ALAT) to 
evaluate nephro- and hepatotoxicity, respectively. 
Immunohistochemistry 
LS174T-PSMA tumors from mice treated with 
tPDT (5 mice per time point) at a NIR radiant 
exposure of 150 J/cm2 or from untreated control mice 
(5 mice) were harvested at 1 h or 24 h after NIR light 
irradiation and fixated in 4% buffered formalin. 
Tissues were subsequently embedded in paraffin and 
sectioned at 4 μm thickness. Tissue sections were 
stained with hematoxylin and eosin (H&E) to 
visualize morphology. An immunohistochemical 
protocol was followed to stain the tissue sections with 
either anti-Ki-67 antibody (1:100 dilution, rabbit 
monoclonal, Thermo Scientific), anti-caspase-3 
antibody (1:4000 dilution, rabbit anti human/mouse 
cleaved caspase-3, Cell Signaling) or anti-ƴH2AX 
antibody (1:1000 dilution, rabbit anti H2AX, Cell 
Signaling). Briefly, slides were deparaffinized by 
xylene wash and rehydrated using ethanol. Antigen 
retrieval was performed with 10 mM citrate pH 6.0 in 
PT-Module (10 min, 96 °C). Endogenous peroxidase 
activity was quenched with 3% H2O2 for 10 min. After 
preincubation with 20% normal goat serum for 30 
min, the slides were incubated with rabbit anti 
anti-caspase antibody (1:4000) respectively rabbit anti 
H2AX (1:1000) in a humidified chamber at 4°C 
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overnight in the dark. After preincubation with 20% 
normal swine serum, the slides were incubated with 
rabbit anti Ki-67 (1:100) for 60 min at room 
temperature. Subsequently, the slides were washed 3 
times with 10 mM PBS. The slides stained with 
caspase-3 and H2AX were incubated with 
goat-anti-rabbit-biotin (1:200 Vector Laboratories) for 
30 min at RT after washing with PBS followed by the 
incubation with Vectastain Elite ABC kit (Vector 
Laboratories) for 30 min. The slides stained with Ki-67 
were incubated with the secondary antibody 
swine-anti-rabbit-peroxidase (1:200, DAKO) After 
washing with PBS, the bound antibodies were 
visualized using diaminobenzine (DAB, 
Sigma-Aldrich). All slides were counterstained with 3 
times diluted hematoxylin (Klinipath) for 5 seconds 
and mounted with a cover slip (permount, Fisher 
Scientific).  
 Immunohistochemical stainings were analyzed 
by two observers (CF and SL) in consensus and 
categorized using an ordinal 5-point scale ranging 
from 0 (no staining), 1 (weak staining), 2 (intermediate 
staining), 3 (intense staining) to 4 (very intense 
staining). In total, the observers scored 5 NIR treated 
tumors per time point (1 vs. 24 h post irradiation) and 
per staining (caspase-3, yH2AX, and Ki-67). In 
addition, one or two non-irradiated tumors were 
included as control. 
Statistical analysis 
Survival curves of median survival and 
progression-free survival were compared with the 
log-rank (Mantel-Cox) test and Gehan-Breslow- 
Wilcoxon test using GraphPad Prism version 5.03. 
The time interval until tumors reached a size of 1000 
mm3 in the different treatment groups and the control 
group was compared with the two-way ANOVA. 
Differences in tumor growth rate between the 
treatment groups and the control group were 
compared with repeated-measures ANOVA and 
New-Keuls multiple comparison post analysis. A 
p-value below 0.05 was considered significant. 
Results 
111In-DTPA-D2B-IRDye700DX is stable in 
serum and PBS 
111In-DTPA-D2B-IRDye700DX was stable in 
mouse serum and PBS directly after radiolabeling 
(radiochemical purity 98.7 ± 0.2 and 98.9 ± 1.4, 
respectively) and remained stable at 0.5 (99.1 ± 0.6 and 
99.1 ± 0.4), 2.5 (99.2 ± 0.2 and 98.6 ± 0.4), 6 (98.7 ± 0.4 
and 98.5 ± 0.3), and 24 h (99.6 ± 0.1 and 97.7 ± 0.9, 
respectively). Fluorescence intensity was set to 100% 
at t=0. Fluorescence intensity slowly decreased from 
101.0, 94.3, and 93.4% after 0.5, 2.5, and 6h to 90.5% 
after 24h in PBS. In serum, fluorescence intensity was 
115.8, 129.3, 122.2, and 118.2% after 0.5, 2.5, 6, and 24h. 
111In-DTPA-D2B-IRDye700DX specifically 
binds to PSMA-expressing cells 
The immunoreactive fractions of 111In-DTPA- 
D2B-IRDye700DX and 111In-DTPA-D2B were 87% and 
84%, respectively, which indicates that the 
immunoreactivity of the D2B antibody was largely 
preserved after the two conjugation procedures. The 
competitive binding assay revealed an IC50 of D2B of 
4.0 nM (95% confidence interval: 3.0 – 5.4 nM). The 
IC50 of DTPA-D2B-IRDye700DX did not differ 
significantly from this value (2.1 nM, 95% confidence 
interval: 1.9 – 2.4 nM, p>0.05). 
111In-DTPA-D2B-IRDye700DX is gradually 
internalized by PSMA-expressing cells 
111In-DTPA-D2B-IRDye700DX and 111In-DTPA- 
D2B gradually and specifically internalized into 
PSMA-expressing LS174T-PSMA cells (Figure 1A and 
B). The internalized fraction increased and reached a 
plateau during the first 24 h. After 48 h, 40.3 ± 2.6% 
and 41.6 ± 0.2% of the added activity of 
111In-DTPA-D2B-IRDye700DX and 111In-DTPA-D2B, 
respectively, was internalized. Internalization of 
111In-DTPA-D2B-IRDye700DX and 111In-DTPA-D2B 
was blocked by addition of an excess of unlabeled 
D2B, leading to an internalized fraction of 0.9 ± 0.0% 
and 0.9 ± 0.0%, respectively. 
DTPA-D2B-IRDye700DX induces 
PSMA-specific tumor cell destruction upon 
NIR light exposure 
PSMA+ LS174T-PSMA cells were incubated with 
DTPA-D2B-IRDye700DX and irradiated with NIR 
light to analyze cellular toxicity of tPDT. After 
incubation of LS174T-PSMA cells with 10 µg/mL 
DTPA-D2B-IRDye700DX for 1 h, cells were irradiated 
at NIR radiant exposures of 2, 5, 10, 30, 50, 100, and 
150 J/cm2. To measure phototoxic cell destruction, a 
CellTiterGlo® luminescent cell viability assay was 
performed, determining the percentage of viable cells 
in culture based on quantitation of the ATP present, 
an indicator of metabolically active cells. Cellular 
phototoxicity occurred only in PSMA-expressing 
LS174T-PSMA cells incubated with 
DTPA-D2B-IRDye700DX and treated with NIR light. 
PSMA-negative LS174T-wildtype cells remained 
viable when treated with both conjugate and NIR 
light, which confirms PSMA-specificity of the therapy 
(104.1 ± 4.1%, 90.9 ± 4.2%, 106.2 ± 2.0%, 104.0 ± 2.3%, 
100.1 ± 3.2%, 104.4 ± 3.1%, 105.5 ± 5.9%, and 111.3 ± 
4.2% viable cells after NIR exposure of 0, 2, 5, 10, 30, 
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50, 100, and 150 J/cm2). In PSMA-expressing tumor 
cells, cellular phototoxicity increased with escalating 
NIR light irradiation intensities. After NIR radiant 
exposures of 0, 2, 5, 10, 30, 50, 100, and 150 J/cm2, 93.9 
± 2.7%, 103.5 ± 1.9%, 102.2 ± 3.6%, 99.0 ± 5.3%, 52.1 ± 
1.7%, 45.0 ± 1.2%, 23.9 ± 0.9%, and 15.3 ± 1.5% of the 
PSMA-positive LS174T-PSMA tumor cells were viable 
(Figure 1C).  
111In-DTPA-D2B-IRDye700DX efficiently 
accumulates in PSMA-expressing tumors 
111In-DTPA-D2B-IRDye700DX specifically 
accumulated in the s.c. PSMA-positive LS174T-PSMA 
tumors, reaching 31.1 ± 5.0 percentage of the injected 
dose per gram (% ID/g) at 24 h after injection, 32.3 ± 
8.2% ID/g at 48 h after injection, 33.8 ± 3.6% ID/g at 
72 h after injection, and 31.7 ± 9.7% ID/g at 168 h after 
injection (Figure 2A). No significant difference in 
tumor uptake were observed at the different time 
points (one-way Anova, p=0.96). The uptake of 
111In-DTPA-D2B-IRDye700DX was significantly lower 
in all healthy tissues. Tracer accumulation in blood 
decreased from 6.7 ± 1.0% ID/g at 24 h p.i. to 1.9 ± 
0.4% ID/g at 168 h after injection. A similar trend was 
observed for the kidneys, in which tracer uptake 
decreased from 5.5 ± 0.2% ID/g at 24 h p.i. to 1.3 ± 
0.2% ID/g at 168 h after injection. Hepatic uptake 
ranged from 9.3 ± 2.3% ID/g at 24 h after injection to 
8.1 ± 1.4% ID/g at 168 h after injection, uptake in the 
spleen reached a maximum of 8.9 ± 0.6% ID/g at 24 h 
after injection. Pre-operatively performed 
µSPECT/CT and NIRF imaging was performed 24, 48, 
72, and 168 h p.i. and tumors were clearly visualized 
with both modalities for all time points. 
Representative images acquired at 24 h p.i. are 
displayed in Figure 2B. Intra-operative NIRF imaging 
could be used for guided resection of the tumors. 
 
 
Figure 1: Internalization kinetics of 111In‐DTPA-D2B (A) and 111In‐DTPA‐D2B‐IRDye700DX (B) in LS174T‐PSMA cells. Binding and internalization is presented as 
the percentage of the added activity (mean ± SD). C) Cell viability of LS174T-PSMA cells in vitro following incubation with 10 µg/mL DTPA-D2B-IRDye700DX and 
NIR light irradiation with radiant exposures of 2, 5, 10, 30, 50, 100, and 150 J/cm2. 
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Figure 2: A) Biodistribution of 111In-DTPA-D2B-IRDye700DX (30 µg and 8 MBq per mouse, n=5 per group) in the PSMA-expressing tumors and several healthy 
tissues. B) NIRF (top) and µSPECT/CT (bottom) in mice (different mice per time point were used) with s.c. LS174T-PSMA tumors at 24, 48, 72, and 168h after 
injection of 30 µg of 111In-DTPA-D2B-IRDye700DX. 
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Figure 3: Biodistribution of different doses of 111In-DTPA-D2B-IRDye700DX (24, 80, or 240 µg/mouse, 8 MBq/mouse, n=5 mice per group) at 24 h after injection. 
One group of mice received 300 µg of D2B i.v. 2 days prior to i.v. application of 24 µg of 111In-DTPA-D2B-IRDye700DX to block the uptake (Xs cold condition). 
 
 As no significant difference in tumor uptake at 
the different time points was observed, the 
dose-finding study was analyzed at 24 h p.i. to 
minimize the chance of degradation of the 
dual-labeled tracer in vivo when NIR light irradiation 
will be performed. Highest tumor uptake (% ID/g) 
was observed for a conjugate dose of 24 µg/mouse, 
reaching 32.7 ± 6.8% ID/g. For conjugate doses of 80 
and 240 µg/mouse, tumor uptake decreased to 22.7 ± 
4.6 and 13.2 ± 4.1% ID/g, respectively (Figure 3). A 
similar trend was observed for hepatic uptake, 
decreasing from 10.8 ± 0.9% ID/g at a dose of 24 
µg/mouse to 10.6 ± 0.7% ID/g and 8.7 ± 1.2% ID/g for 
80 and 240 µg/mouse, respectively.  
PDT using DTPA-D2B-IRDye700DX inhibits 
tumor growth and significantly improves 
survival 
In the PDT therapy experiment in xenografted 
mice, several treatment conditions were tested. One 
group of 7 mice with s.c. PSMA+ LS174T-PSMA 
tumors was included that received NIR light 
irradiation once, at 24 h p.i. at an intensity of 150 
J/cm2. In addition, 3 groups of mice were included 
that received 3 NIR light exposures (at 24, 48, and 72 h 
after injection of the conjugate) at intensities of 50, 100, 
or 150 J/cm2. Moreover, one control group was 
included which did not receive the conjugate, but was 
irradiated with NIR light and one control group was 
included which received neither the conjugate nor 
NIR light irradiation. Mean tumor sizes at the day of 
NIR treatment were 91.9 ± 32.6 mm3 (group: 1x 150 
J/cm2), 28.6 ± 21.7 mm3 (group: 3x 150 J/cm2), 33.3 ± 
33.7 mm3 (group: 3x 100 J/cm2), 29.6 ± 37.2 mm3 
(group: 3x 50 J/cm2). Tumor sizes in the 1x 150 J/cm2 
group were significantly higher compared to the other 
groups (p<0.05).  
Mean tumor size in the control group that was 
irradiated but did not receive the conjugate was 31.7 ± 
35.3 mm3 and in the group that received neither 
conjugate nor NIR light exposure was 45.5 ± 21.7 mm3.  
Tumor growth after treatment with 1x 150 J/cm2 
as well as with 3x 50, 100, or 150 J/cm2 in individual 
mice is depicted in Figure 4. Analysis of survival 
(until tumors reached a size of 1,000 mm3 or until 
humane endpoints were reached) revealed 
significantly longer overall survival in mice that 
received 80 µg of the conjugate followed by a single 
NIR light exposure at 24h post injection at a NIR light 
exposure of 150 J/cm2 (median survival 73 days) 
compared to mice that neither received the conjugate 
nor received NIR light exposure (median survival 16 
days) and mice that received NIR light exposure only 
(median survival 16 days) (p=0.0453) (Figure 4A). In 
addition, progression-free survival was significantly 
prolonged in mice treated with 80 µg of the conjugate 
followed by NIR light of 1x 150 J/cm2 
(progression-free survival 61 days) as compared to 
both control groups (progression-free survival of 2 
and 1 days, respectively) (p=0.0229) (Figure 4B). 
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However, three out of seven mice out of the treatment 
group died three days after NIR light exposure (these 
mice were excluded from further analysis). Upon 
necropsy/autopsy, no signs of skin/tissue/organ 
damage due to treatment were found. All remaining 
four mice out of the treatment group developed 
eschars at the tumor side within 2 days after NIR light 
exposure, which healed within 7-14 days and resulted 
in the formation of a scar. None of the mice out of the 
two control groups developed eschars and 
subsequent scars. 
To evaluate whether fractionated NIR light 
exposures increase the therapeutic efficacy, groups of 
mice were included which received NIR light 
irradiation of 50, 100, or 150 J/cm2 at 24, 48, and 72 h 
after i.v. administration of 80 µg of the conjugate. 
Compared to the control groups, NIR irradiation 
regimens of 3x 50 and 3x 100 J/cm2 significantly 
increased progression-free and overall survival 
(p=0.0029) (Figure 4A and B). Progression-free 
survival (9.5 and 15 days, respectively, p=0.1606) and 
overall survival (32 and 36 days, respectively, 
p=0.5566) were not significantly different between 
mice treated with 3x 50 and 3x 100 J/cm2. Compared 
to a single NIR light exposure of 150 J/cm2, 
progression-free survival upon fractionated NIR light 
exposure of 3x 50 (p=0.0039) and 3x 100 (p=0.0148) 
J/cm2 was significantly reduced (Figure 4B). For 
overall survival similar observations were made; 
single treatment with 150 J/cm2 of NIR light resulted 
in significantly prolonged overall survival compared 
to fractionated treatment with 3x 100 J/cm2 of NIR 
light (p=0.0294). None of the mice treated with 3x 50 
J/cm2 developed eschars/scars after NIR light 
exposure.  
Compared to mice treated with 1x 150 J/cm2, 
progression-free and overall survival were not 
significantly different between mice treated with 3x 
150 J/cm2 (p=0.8644). Six out of 7 mice (86%) treated 
with 3x 150 J/cm2 developed eschars/scars after NIR 
light exposure. 
 
 
Figure 4: Kaplan-Meier plots of overall (A) and progression-free survival (B) (7 mice/group, excluded mice are indicated with apostrophes in the graphs) and tumor 
growth (C-F) of male BALB/c nude mice with s.c. PSMA+ LS174T-PSMA tumors after i.v. injection of 80 µg of DTPA-D2B-IRDye700DX, followed by exposure to 
different NIR light irradiation regimens. In panel C-F, tumor growth in mice that did not receive the conjugate but where irradiated with the highest NIR light dose 
(3x 150 J/cm2) (control group), was compared to that in mice treated with a single administration of the conjugate followed by NIR light exposure of 3x 150 J/cm2 (C), 
1x 150 J/cm2 (D), 3x 100 J/cm2 (E), and 3x 50 J/cm2 (F). 
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To ensure that DTPA-D2B-IRDye700DX itself 
(without NIR light exposure) has no therapeutic effect 
either, overall survival was evaluated in mice treated 
with the conjugate only and compared to that of mice 
treated with neither conjugate nor light and to mice 
that received NIR light only (without prior conjugate 
administration) in a subsequent experiment. Overall 
survival between these groups was not significantly 
different (12, 13, and 14 days, respectively, p=0.5902). 
In this experiment, therapeutic efficacy was also 
tested in mice with s.c. PSMA-negative 
LS174T-wildtype tumors which received 80 µg of the 
conjugate followed by NIR light exposure (1x 100 
J/cm2) at 24h p.i.. Compared to the three control 
groups, overall survival (21 days) was significantly 
prolonged (p=0.0283).  
To evaluate therapy-induced changes in the 
tumors, LS174T-PSMA tumors treated with 80 µg of 
DTPA-D2B-IRDye700DX and harvested 1 or 24 h after 
NIR light irradiation (150 J/cm2), and untreated 
control tumors were analyzed immunohistoche-
mically (Figure 5).  
 
 
Figure 5: A) HE, PSMA, caspase-3, ƴH2aX, and Ki-67 stainings of s.c. PSMA+ LS174T-PSMA tumors after i.v. administration of PBS (left) or 80 µg of 
111In-DTPA-D2B-IRDye700DX (middle (tumors dissected 1h after tPDT) and right (tumors dissected 24h after tPDT)). All scale bars indicate 500 µm. B) Staining 
intensity of immunohistochemical stainings of treated (n=5) and non-treated tumor. 
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Categorization of the immunohistochemical 
stainings revealed that treated tumor sections showed 
higher expression of caspase-3 and ƴH2AX compared 
to non-treated tumors. Caspase-3 and ƴH2AX 
expression were higher in tumors resected at 24 h 
after NIR light exposure compared to 1 h post 
irradiation. Ki-67 stainings were performed to show 
viability of the tumor sections. 
PDT using DTPA-D2B-IRDye700DX does not 
induce nephro- or hepatotoxicity 
To evaluate potential nephro- and hepatotoxcity 
of PSMA-tPDT, blood samples were obtained prior to 
any treatment from treated and non-treated mice 
(with conjugate and without NIR exposure, without 
conjugate and with NIR exposure, and with both 
conjugate and NIR light on mice with PSMA-negative 
tumors) 1 week after treatment. No significant 
changes in aspartate/alanine transaminase 
(AST/ALT) were observed between the treatment 
groups before and after therapy (p=0.0660 for ALT 
and p=0.1311 for AST). Creatinine levels were 
significantly increased in the treatment group at 1 
week after therapy compared to baseline levels 
(p=0.001), however, this elevation in creatinine levels 
was reversible and creatinine levels measured directly 
after euthanasia in these mice were restored. 
Discussion 
Despite improvements in PCa oncological 
surgery (biochemical) recurrences frequently occur, 
which may be attributed to two major issues: first, the 
translation from pre-operatively obtained images to 
the surgical field can be extremely challenging for 
surgeons, particularly in the abdominal region. Thus, 
some lesions may not be removed and may cause 
disease recurrence. Second, wide local excision of 
tumors may be restricted due to close proximity of the 
rectum, sphincter and erectile nerves and lead to 
incomplete surgical removal. To address both issues, 
in this study a multimodal anti-PSMA targeting agent 
for highly specific pre- and intra-operative tumor 
localization, surgical guidance, and PSMA-targeted 
tumor cell destruction using tPDT was characterized 
in vivo.  
So far, several approaches for antibody-targeted 
PDT have been developed. Mangadlao et al. used the 
phthalocyanine-based photosensitizer Pc4 in a 
preclinical study investigating the potential of 
PSMA-targeted gold nanoparticles containing Pc4 as 
imaging and PDT agent [28]. In the majority of these 
studies, the phthalocyanine IRDye700DX was used as 
a photosensitizer, as it absorbs light in the 
near-infrared (NIR) range, which allows deeper tissue 
penetration compared to visible light. In addition, 
IRDye700DX can be covalently conjugated to 
targeting molecules using its NHS ester. Moreover, 
IRDye700DX has a higher extinction coefficient 
(2.1x105 M-1cm-1 at 689 nm) than non-NIR 
photosensitizers [8]. This might be advantageous, as 
low extinction coefficients require conjugation of large 
numbers of photosensitizers to a targeting molecule, 
which might decrease the binding affinity and/or the 
tumor targeting characteristics of the targeting vehicle 
[29]. However, efficacy of photodynamic therapy may 
also dependent upon singlet oxygen quantum yield. 
Photosensitizers with higher singlet oxygen quantum 
yields are generally more effective in generating 
reactive singlet oxygen species. 
In the present study, 111In-DTPA-D2B- 
IRDye700DX was shown to be stable in serum and 
PBS, and it specifically binds to and is gradually 
internalized by PSMA-expressing cells. Binding and 
internalization capacity were similar to unconjugated 
D2B [19, 27]. In vitro, we demonstrated that 
DTPA-D2B-IRDye700DX induced PSMA-specific 
tumor cell destruction upon NIR light exposure. In 
vivo, 111In-DTPA-D2B-IRDye700DX efficiently 
accumulated in PSMA-expressing tumors. Ex vivo 
biodistribution studies also revealed tracer 
accumulation in the liver and spleen, which may be 
attributed to relative lipophilicity of IRDye700DX. To 
avoid major changes in biodistribution and 
accumulation in liver and spleen, the molar 
substitution ratio of IRDye700DX to antibody was 
limited to 3.3 : 1, which allowed NIRF imaging and 
tPDT in the tumor. Biodistribution was determined at 
different time points to identify the time point with 
the highest tumor accumulation, which was assumed 
the optimal time point for NIR light irradiation. As no 
significant difference in tumor accumulation was 
observed between the different time points after 
injection, the earliest time point (24 h p.i.), in line with 
previous studies [8], was selected for subsequent in 
vivo studies for two reasons: first, in clinical settings, it 
is more practical to perform imaging/therapy early 
after injection. Second, at later time points after 
injection, degradation of the antibody-IRDye700DX 
conjugate might occur by either breakdown in the 
liver or in the tumor after internalization. In the 
present study, at 24 h after administration 
PSMA-expressing tumors were clearly visualized on 
pre-operative µSPECT/CT and intra-operative NIRF 
images, which could also be used for image-guided 
resection of the tumors.  
In a biodistribution experiment, three different 
tracer doses were evaluated. In theory, anti-tumor 
efficacy of tPDT should increase with higher amounts 
of photosensitizer in the tumor, which can be reached 
by escalating the tracer dose. Mitsunaga et al. showed 
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that anti-tumor efficacy using 300 µg the anti-EGFR 
mAb panitumumab conjugated to IRDye700DX was 
higher compared to 50 µg [8]. However, at a certain 
dose, saturation of the epitopes in the tumor will 
occur, leading to non-specific localization and high 
amounts of photosensitizer in surrounding tissues. 
Indeed, Mitsunaga and colleagues observed higher 
background levels in mice administered with 300 µg 
instead of 50 µg of the conjugate [8]. To minimize 
non-specific accumulation in tumor and other organs 
but still be able to reach sufficient therapy efficacy, we 
selected the tracer dose of 80 µg for tPDT studies.  
In previous studies, the radiant exposure of NIR 
light applied to tumors typically ranged between 30 
and 100 J/cm2 [8, 30, 31]. In the present study, efficacy 
of single and multiple administrations of low and 
high radiant exposures were evaluated (50, 100, or 150 
J/cm2). NIR light irradiation with all three radiant 
exposures caused significant prolongation of 
progression-free survival from 1-2 to 61 days and 
overall survival from 16 to 73 days compared to 
non-treated control tumors. Chen et al. performed 
PSMA-tPDT using the low-molecular-weight 
theranostic photosensitizer, YC-9, which was 
synthesized by conjugating IRDye700DX with a 
PSMA targeting Lys-Glu-urea [32]. YC-9 was applied 
four times within 48 h followed by NIR light exposure 
of 100 J/cm2 at 4h p.i.. The authors report a 
prolongation of overall survival of mice with s.c. 
PSMA-expressing tumors from 24-30 to 57 days upon 
exposure to 100 J/cm2 of NIR light [32]. In the present 
study, the effect of repeated, fractionated NIR light 
exposure was evaluated. As antibody molecules 
circulate longer compared to small molecules, the 
conjugate was applied only once in the present study. 
While multiple fractionated NIR light exposures 
resulted in prolonged progression-free and overall 
survival compared to control groups, single 
administration of 150 J/cm2 caused the most 
significant benefit for progression-free and overall 
survival, which was similar to administration of 3x 
150 J/cm2. However, the majority of mice treated with 
these high NIR light doses developed side-effects 
(eschar and scar formation), while side-effects were 
less prominent and frequent in mice treated with 
lower doses. Okuyama and colleagues have shown 
that skin damage after NIR light exposure may be 
attributed to heat developed by the LED system [33]. 
 As biodistribution revealed high liver/spleen 
uptake, hepatotoxicity was evaluated in the present 
study. However, no hepatotoxicity was observed. In 
addition, as NIR light irradiation can be applied 
locally, liver and spleen uptake are not expected to 
cause side effects of the therapy. Observed 
nephrotoxicity was mild and reversible in this study 
and may be due to reduced fluid intake of treated 
mice directly after the procedure and increased fluid 
metabolism due to healing processes.  
Compared to the three control groups, overall 
survival was significantly prolonged in the 
PSMA-negative control tumors. One explanation for 
this may be nonspecific localization of the conjugate 
in the tumor due to the EPR (enhanced permeability 
and retention) effect.  
To illustrate therapy-induced changes in the 
tumors, immunohistochemical assessments were 
performed on LS174T-PSMA tumors harvested 1 or 24 
h after NIR light irradiation, as well as on untreated 
control tumors. Compared to controls, expression of 
ƴH2AX and caspase-3 were significantly higher in 
treated tumor sections, suggesting the induction of 
DNA double strand breaks and apoptosis following 
treatment. Although these observations need to be 
investigated further in a larger study, these data 
support the observed changes in tumor growth. One 
limitation of this study is that no isotype control for 
the antibody was used, so potential contributions of 
inflammatory uptake through FcR interactions cannot 
be discriminated from specific epithelial binding.  
Here, we have shown feasibility of 111In-DTPA- 
D2B-IRDye700DX for pre- and intra-operative 
detection of PSMA+ tumors with radionuclide and 
NIR fluorescence imaging and PSMA-targeted PDT in 
a transfected tumor model which stably expresses 
PSMA. In the next step, this approach will be 
evaluated in prostate cancer cell lines that naturally 
express PSMA. 
In the clinical setting, this tPDT approach could 
be embedded into a multimodal approach in which 
the theranostic targeting agent could be used for 
pre-operative visualization of tumor lesions to 
evaluate the tumor load and the localization of the 
tumor lesions. In addition, the targeting molecule 
could be used during surgery for guidance to 
deeper-seeded tumor lesions using a gamma probe. 
Once these lesions have been brought to the surface, 
the fluorescent signal of the multimodal targeting 
agent can be used to visually guide the surgeon 
towards precise resection of the lesions. Finally, in 
areas where wide local excision is precluded, the 
targeting agent could be used for PSMA-tPDT to 
destroy residual tumor tissue that could not be 
removed surgically. The elimination of these PSMA+ 
residual tumor cells is crucial as patients with 
PSMA-expressing tumors show an increased rate of 
biochemical recurrence [34] and the well-established 
role of PSMA in the aggressiveness of malignant cells 
[35]. 
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Conclusion 
In the present study, the development of the 
theranostic multimodal agent 111In-DTPA-D2B- 
IRDye700DX was described and optimized in vitro 
and in vivo in a mouse model to improve management 
of PCa. It was demonstrated that 
111In-DTPA-D2B-IRDye700DX can be used for 
pre-operative visualization of tumors using 
µSPECT/CT and for intra-operative tumor 
localization using NIRF imaging. Moreover, NIRF 
imaging can be used to guide surgical removal where 
possible and/or guide (additional) PSMA-tPDT in 
areas where tumor remnants cannot be removed 
surgically due to their proximity to important 
surrounding structures such as nerves innervating the 
urinary bladder or erectile functions. It was 
demonstrated that PSMA-tPDT can efficiently inhibit 
growth of PSMA-expressing tumors and significantly 
prolong median survival.  
These preclinical findings encourage future 
clinical studies with radiolabeled targeting molecules 
conjugated to IRDye700DX to improve diagnostic 
imaging, provide surgical guidance, and enable tPDT 
of non-resectable tumor remnants.  
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